高雄醫學大學圖書館 |

語系/ Language: 繁體中文

登入

回首頁

標靶藥物作為表皮生長因子接受器突變之肺腺癌晚期第一線治療之成效分析 = ...

黃茗沂

標靶藥物作為表皮生長因子接受器突變之肺腺癌晚期第一線治療之成效分析 = Cost-effectiveness of targeted therapies as the first-line treatment for advanced lung adenocarcinoma with epidermal growth factor receptor mutation

紀錄類型:	書目-語言資料,印刷品 : 單行本
並列題名:	Cost-effectiveness of targeted therapies as the first-line treatment for advanced lung adenocarcinoma with epidermal growth factor receptor mutation
作者:	黃茗沂
出版地:	[高雄市]
出版者:	[撰者];
出版年:	民108[2019]
面頁冊數:	144面圖 : 30公分;

標靶藥物作為表皮生長因子接受器突變之肺腺癌晚期第一線治療之成效分析 = Cost-effectiveness of targeted therapies as the first-line treatment for advanced lung adenocarcinoma with epidermal growth factor receptor mutation
黃茗沂

標靶藥物作為表皮生長因子接受器突變之肺腺癌晚期第一線治療之成效分析 = Cost-effectiveness of targeted therapies as the first-line treatment for advanced lung adenocarcinoma with epidermal growth factor receptor mutation / 黃茗沂(Ming-Yi Huang)撰 - [高雄市] : [撰者], 民108[2019]. - 144面 ; 圖 ; 30公分.
含參考書目.

標靶藥物作為表皮生長因子接受器突變之肺腺癌晚期第一線治療之成效分析 = Cost-effectiveness of targeted therapies as the first-line treatment for advanced lung adenocarcinoma with epidermal growth factor receptor mutation
LDR:00906nam0 2200181 450 001 322968
005 20220304141212.0
010 0 $b 平裝
100 $a 20191119y2019 y0chiy09 e
101 0 $a eng $d chi $d eng
102 $a tw
200 1 $a 標靶藥物作為表皮生長因子接受器突變之肺腺癌晚期第一線治療之成效分析 $d Cost-effectiveness of targeted therapies as the first-line treatment for advanced lung adenocarcinoma with epidermal growth factor receptor mutation $f 黃茗沂(Ming-Yi Huang)撰
210 $a [高雄市] $c [撰者] $d 民108[2019]
215 0 $a 144面 $c 圖 $d 30公分
314 $a 指導教授:楊奕馨
320 $a 含參考書目
328 $a 碩士論文--高雄醫學大學藥學系臨床藥學碩士班
510 1 $a Cost-effectiveness of targeted therapies as the first-line treatment for advanced lung adenocarcinoma with epidermal growth factor receptor mutation
681 $a 008 415 $b 8354 2019
700 1 $a 黃茗沂 $3 479469